# Abaloparatide

A newer bone-building daily injection that works through the same receptor as teriparatide.

Also called: Tymlos, Eladynos
Source page: https://peplogue.com/peptides/abaloparatide/
Reviewed: 2026-10-12. Not medical advice.

## How it works

- Where it acts: PTH1 receptors, in a way that favours bone building.
- What it changes: It builds new bone.
- What people notice: Fewer spine fractures. Dizziness, a fast heartbeat and high blood calcium can occur.

## What the evidence shows

- **Osteoporosis at high risk of fracture**: Proven. Over 18 months, new spine fractures fell from 4.2% to 0.6%, and other fractures from 4.7% to 2.7%.

## Side effects and risks

- serious: Bone cancer (osteosarcoma) occurred in rats.
- common: Dizziness, a racing heart and nausea shortly after a dose.
- common: Raised calcium in blood and urine.

Who should avoid it: Children and teenagers whose bones are still growing, and people with Paget's disease, past radiation to the skeleton, or bone tumors.

## How it is taken

An 80 microgram injection under the skin once a day. The US label advises against more than two years in a lifetime. In the EU and UK the limit is 18 months.

## Legal status

- United States: undefined. Tymlos, for women and men at high risk of fracture.
- European Union: undefined. Eladynos, for postmenopausal women.
- Spain: undefined. Eladynos is authorised and marketed in Spain (CIMA), prescription only. SNS funding not verified.
- Germany: undefined. Eladynos on sale since 15 Apr 2024 for postmenopausal osteoporosis, Rx only. G-BA (Oct 2024): added benefit not proven.
- France: undefined. Eladynos is EU-authorised, so authorised in France. We could not verify French sale, price or reimbursement.
- Italy: undefined. Eladynos (EU-authorised 2022): AIFA publishes a Nota 79 piano terapeutico for it (6 months, max 18). Launch and class details not checked.
- Netherlands: undefined. Eladynos (postmenopausal osteoporosis) is listed and EU-authorised. Reimbursement and pharmacy stock were not confirmed.
- United Kingdom: undefined. Eladynos.
- Canada: undefined
- Australia: undefined

## Questions people ask

**How well does abaloparatide work?**

Over 18 months, new spine fractures fell from 4.2% to 0.6%, and other fractures from 4.7% to 2.7%.

**How is abaloparatide different from teriparatide?**

It is a newer bone-building daily injection that works through the same receptor as teriparatide, in a way that favours bone building.

**How long can you take abaloparatide?**

The US label advises against more than two years in a lifetime. In the EU and UK the limit is 18 months.

**What are the side effects of Tymlos?**

Dizziness, a racing heart and nausea shortly after a dose, and raised calcium in blood and urine. Bone cancer (osteosarcoma) occurred in rats.

**Is Tymlos approved for men?**

In the US, Tymlos is approved for women and men at high risk of fracture. In the EU, Eladynos is for postmenopausal women.

## Sources

- Tymlos US prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=712143d9-e21e-4013-bb3b-3426a21060a8
- EMA: Eladynos product page: https://www.ema.europa.eu/en/medicines/human/EPAR/eladynos